In particular, STING agonists may have the greatest impact on HPV+ tumors, as they already have elevated infiltration of immune cells, which might assist with current aims to deescalate treatment for patients with HPV+ HNSCC. This evidence concerns the gene STING1 and head and neck squamous cell carcinoma.